Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational approaches for evaluation of isobavachin as potential inhibitor against t877a and w741l mutations in prostate cancer.

Journal of biomolecular structure & dynamics - 1 Apr 2023

Browne Rene Barbie, Goswami Nabajyoti, Borah Probodh, Roy Jayanti Datta

Abstract excerpt

Prostate cancer is the World's second most common cancer, with the fifth-highest male mortality rate. Point mutations such as T877A and W741L are frequently seen in advanced prostate cancer patients, conferring drug-resistance and hence driving cancer growth. Such occurrence of drug resistance in prostate cancer necessitates designing of suitable ligands to ensure better interactions with the receptors which can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Flavonoids

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Ligands

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Mutation

Share to Prostatic Neoplasms

Share to Receptors, Androgen

Source

Identifiers

PMID: 35118933
DOI: 10.1080/07391102.2022.2032353

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational approaches for evaluation of isobavachin as potential inhibitor against t877a and w741l mutations in prostate cancer.PMID 35118933Read ↗

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancerSemantic proximity Read ↗

Deciphering the role of zingiber officinale phytochemicals for the treatment of prostate cancer: Interactions of phytochemicals with androgen receptor prostate cancer mutant H874Y ligand binding domain.Semantic proximity Read ↗

Structural insights into the mechanism of resistance to bicalutamide by the clinical mutations in androgen receptor in chemo-treatment resistant prostate cancer.Semantic proximity Read ↗

Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.Semantic proximity Read ↗

Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studiesSemantic proximity Read ↗

Role of plant derived bioactive compounds against cancerSemantic proximity Read ↗

Isoquinolines alkaloids and cancer metabolism: Pathways and targets to novel chemotherapySemantic proximity Read ↗

A novel small-molecule androgen receptor antagonist selective for the T878A-mutant AR in prostate cancer therapy.Semantic proximity Read ↗

Integrating machine learning driven virtual screening and molecular dynamics simulations to identify potential inhibitors targeting PARP1 against prostate cancerSemantic proximity Read ↗

Virtual Screening of Different Subclasses of Lignans with Anticancer Potential and Based on Genetic ProfileSemantic proximity Read ↗

Screening and identification of phytochemical drug molecules against mutant BRCA1 receptor of breast cancer using computational approaches.Semantic proximity Read ↗

Simulation Studies 3D QSAR and Molecular Docking, on a Point Mutation of Protein Kinase B with Flavonoids Targeting Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.